Key result
Left atrial appendage exclusion devices are a safe and effective alternative to oral anticoagulation for stroke prophylaxis in selected patients with atrial fibrillation.
Why the study?
Do left atrial appendage exclusion devices prevent stroke in patients with atrial fibrillation compared to or as an alternative to therapeutic anticoagulation?
Do left atrial appendage exclusion devices prevent stroke in patients with atrial fibrillation compared to or as an alternative to therapeutic anticoagulation?
Left atrial appendage exclusion devices offer a safe, effective, and potentially cost-effective alternative to oral anticoagulation for stroke prevention in selected patients with atrial fibrillation.
Answers are grounded in this paper and cite their sources.
LAA closure may benefit AC-ineligible AF patients; leaves open need for RCTs versus anticoagulation.
The left atrial appendage (LAA) is implicated as a source of thrombus in the majority of patients with atrial fibrillation (AF) and embolic stroke. Therapeutic anticoagulation (AC) is the mainstay of treatment for stroke prophylaxis in AF. Despite adherence to AC, a significant number of patients are still subtherapeutic. In addition to this, several patients are ineligible for AC because of various reasons, including but not limited to high bleeding risk, ongoing bleeding, and non-compliance. These challenges associated with AC led to efforts looking at mechanical isolation of the LAA. Various endocardial and epicardial devices have been tried for mechanical isolation of the LAA, with variable success. The WATCHMANt (Boston Scientific, Maple Grove, MN) is the first endocardial device that received FDA approval as an alternative for warfarin for stroke prophylaxis in AF. The WATCHMANt (Boston Scientific) is not approved for AC-ineligible patients. The LARIAT s (SentreHEART, Inc., Redwood City, CA) is an epicardially deployed device that has been proposed for AC-ineligible patients. Although not FDA approved, its safety and efficacy had been established in large prospective registries. The current review examines the current literature on AC and LAA exclusion devices in a comparative fashion. The protean effects of LARIAT s (SentreHEART, Inc.) on rhythm and neurohormonal control are also reviewed. We conclude that LAA exclusion devices are an excellent alternative to AC for stroke prophylaxis in AC-eligible (WATCHMANt, Boston Scientific) and ineligible patients (LARIAT s , SentreHEART).
No takes yet. Share an insight, caveat, or question.
Iskandar et al. (2016) conducted a review in Atrial Fibrillation. Left Atrial Appendage Closure vs. Oral anticoagulants was evaluated. Left atrial appendage exclusion devices are a safe and effective alternative to oral anticoagulation for stroke prophylaxis in selected patients with atrial fibrillation.
Synapse has enriched 10 related papers. Consider them for comparative context: